Note 21 - Commitments and Contingencies (Details)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
|
|
|
Jul. 22, 2019
shares
|
Jul. 19, 2019
USD ($)
|
May 14, 2019 |
Apr. 08, 2019
USD ($)
shares
|
Mar. 01, 2019
USD ($)
shares
|
Aug. 01, 2018 |
Jul. 31, 2018
USD ($)
shares
|
Jul. 01, 2018
USD ($)
shares
|
Apr. 06, 2018
USD ($)
|
Jan. 05, 2018
USD ($)
|
Nov. 30, 2017
USD ($)
shares
|
Oct. 09, 2017
USD ($)
|
Aug. 23, 2017
USD ($)
|
Jul. 20, 2016
USD ($)
|
Mar. 31, 2016
USD ($)
|
Aug. 01, 2015
USD ($)
shares
|
Oct. 01, 2014
USD ($)
|
Aug. 31, 2019
USD ($)
|
Aug. 31, 2018
USD ($)
shares
|
Feb. 28, 2019
USD ($)
|
May 31, 2019
USD ($)
|
May 31, 2018
USD ($)
|
Apr. 17, 2017
ft²
|
| Note 21 - Commitments and Contingencies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingency Accrual, Provision |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10,000
|
|
|
|
| Debt Conversion, Original Debt, Amount |
|
$ 12,542
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 13,315
|
|
|
| Employee-related Liabilities, Current |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 176,179
|
|
|
230,119
|
|
|
| Share-based Payment Arrangement, Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
63,222
|
$ 120,138
|
|
|
|
|
| Chief Executive Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 21 - Commitments and Contingencies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Employment Agreement, Term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
| Salary and Wage, Officer, Excluding Cost of Good and Service Sold |
|
|
|
|
|
|
|
$ 150,000
|
|
|
|
|
|
|
|
|
$ 150,000
|
|
|
|
|
|
|
| Deferred Compensation Arrangement with Individual, Description |
|
|
|
|
|
|
|
performance bonus equal to 2% of the annual EBITDA of CLS Nevada, Inc., and annual restricted stock awards of the Company’s common stock in an amount equal to 3% of the annual EBITDA
|
|
|
|
|
|
|
|
|
performance bonus equal to 2% of CLS Labs’ annual EBITDA, up to a maximum annual cash compensation of $1 million (including his base salary), and annual stock options, exercisable at the fair market value of CLS Labs’ common stock on the date of grant, in an amount equal to 2% of its annual EBITDA up to $42.5 million and 4% of its annual EBITDA in excess of $42.5 million
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
annual stock options, exercisable at the fair market value of CLS Labs’ common stock on the date of grant, in an amount equal to 2% of its annual EBITDA up to $42.5 million and 4% of its annual EBITDA in excess of $42.5 million
|
|
|
|
|
|
|
| Employee-related Liabilities, Current |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period |
|
|
|
|
|
|
|
1 year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture (in Shares) | shares |
500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chief Operating Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 21 - Commitments and Contingencies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Employment Agreement, Term |
|
|
2 years
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
| Salary and Wage, Officer, Excluding Cost of Good and Service Sold |
|
|
|
|
|
|
$ 150,000
|
|
|
|
|
|
|
|
|
$ 150,000
|
|
|
|
|
|
|
|
| Deferred Compensation Arrangement with Individual, Description |
|
|
|
|
|
|
performance bonus equal to 2% of the annual EBITDA of CLS Nevada, Inc., and annual restricted stock awards of the Company’ common stock in an amount equal to 3% of the annual EBITDA
|
|
|
|
|
|
|
|
|
performance bonus equal to 2% of the Company’s annual EBITDA, up to a maximum annual cash compensation of $1 million (including his base salary), and annual stock options, exercisable at the fair market value of the Company’s common stock on the date of grant, in an amount equal to 2% of its annual EBITDA up to $42.5 million and 4% of its annual EBITDA in excess of $42.5 million
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
annual stock options, exercisable at the fair market value of the Company’s common stock on the date of grant, in an amount equal to 2% of its annual EBITDA up to $42.5 million and 4% of its annual EBITDA in excess of $42.5 million
|
|
|
|
|
|
|
|
| Employee-related Liabilities, Current |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37,500
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period |
|
|
|
|
|
|
|
1 year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture (in Shares) | shares |
50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| President and Chief Financial Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 21 - Commitments and Contingencies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Salary and Wage, Officer, Excluding Cost of Good and Service Sold |
|
|
|
|
|
|
|
|
|
|
$ 175,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deferred Compensation Arrangement with Individual, Description |
|
|
|
|
|
|
|
|
|
|
performance bonus equal to 2% of the Company’s annual EBITDA, and annual restricted stock awards of the Company’s common stock in an amount equal to 3% of its annual EBITDA
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Description |
|
|
|
|
|
|
|
|
|
|
annual restricted stock awards of the Company’s common stock in an amount equal to 3% of its annual EBITDA
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
600,000
|
|
|
|
|
| President [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 21 - Commitments and Contingencies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Salary and Wage, Officer, Excluding Cost of Good and Service Sold |
|
|
|
|
$ 175,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deferred Compensation Arrangement with Individual, Description |
|
|
|
|
performance bonus equal to 1% of the Company’s annual EBITDA, and annual restricted stock awards in an amount equal to 1% of the Company’s annual EBITDA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares) | shares |
|
|
|
|
500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period |
|
|
|
|
1 year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chief Financial Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 21 - Commitments and Contingencies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Salary and Wage, Officer, Excluding Cost of Good and Service Sold |
|
|
|
$ 110,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period |
|
|
|
|
|
4 months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Former Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 21 - Commitments and Contingencies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Employee-related Liabilities, Current |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 16,250
|
$ 16,250
|
|
| Building [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 21 - Commitments and Contingencies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Area of Real Estate Property (in Square Feet) | ft² |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,392
|
| Lessee, Operating Lease, Term of Contract |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
72 months
|
| Lessee, Operating Lease, Renewal Term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10 years
|
| Unpaid Accrued Salary Converted to Convertible Note [Member] | Convertible Debt [Member] | Chief Executive Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 21 - Commitments and Contingencies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt Conversion, Original Debt, Amount |
|
|
|
|
|
|
|
|
$ 37,500
|
$ 37,500
|
|
$ 39,521
|
$ 62,500
|
$ 250,000
|
$ 112,500
|
|
|
|
|
|
|
|
|
| Deposit [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 21 - Commitments and Contingencies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingency Accrual, Provision |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
|
|
| Rent Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 21 - Commitments and Contingencies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingency Accrual, Provision |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,699
|
|
|
|
| Remaining Amounts Due Under Lease [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 21 - Commitments and Contingencies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss Contingency Accrual, Provision |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 30,000
|
|
|
|
| One Time Signing Bonus [Member] | Chief Executive Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 21 - Commitments and Contingencies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares) | shares |
|
|
|
|
|
|
|
500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period |
|
|
|
|
|
|
|
1 year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| One Time Signing Bonus [Member] | Chief Operating Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 21 - Commitments and Contingencies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares) | shares |
|
|
|
|
|
|
50,000
|
|
|
|
|
|
|
|
|
250,000
|
|
|
|
|
|
|
|
| Share-based Payment Arrangement, Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 327,500
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period |
|
|
|
|
|
|
1 year
|
|
|
|
|
|
|
|
|
1 year
|
|
|
|
|
|
|
|
| One Time Signing Bonus [Member] | President and Chief Financial Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 21 - Commitments and Contingencies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period |
|
|
|
|
|
|
|
|
|
|
1 year
|
|
|
|
|
|
|
|
|
|
|
|
|
| One Time Signing Bonus [Member] | Chief Financial Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Note 21 - Commitments and Contingencies (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares) | shares |
|
|
|
50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period |
|
|
|
1 year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|